This article evaluates the efficacy and safety of single-agent sapanisertib, and of sapanisertib plus the PI3Kα inhibitor TAK-117, versus everolimus in patients with advanced clear cell renal cell carcinoma that had progressed on or after VEGF-targeted therapy. The gene discussed is VEGFA; the disease is clear cell renal carcinoma.